SAN DIEGO, CA — September 10, 2025 — Leads & Copy — Revelation Biosciences, Inc. (NASDAQ:REVB) presented groundbreaking activity data from its Phase 1b PRIME clinical study on stage 3 and 4 chronic kidney disease (CKD) patients, revealing that Gemini normalized inflammatory response at the cellular level.
The primary endpoint of evaluating the safety and tolerability of escalating doses of Gemini was met. Gemini significantly reduced inflammatory activity and restored normal cellular response to stimuli, as measured in peripheral blood mononuclear cells (PBMCs) isolated from patients.
Principal Investigator Adam Horeish, MD, from Balboa Research, noted the shocking activity observed with a single dose of Gemini, suggesting a meaningful step forward in addressing immune dysregulation in CKD patients. Principal Investigator Pablo Pergola, MD, PhD, from Clinical Advancement Center, PLLC, highlighted the potential breakthrough in treating inflammation and improving patient outcomes.
The PRIME study enrolled 40 patients and analyzed PBMCs for background inflammation and response to stimulation. Results showed that Gemini significantly reduced inflammation in patients with high background PBMC activity and corrected immunoparalysis. Gemini administration was well-tolerated at the target dose, with mild adverse events reported.
James Rolke, CEO of Revelation, expressed optimism about Gemini’s potential and anticipates discussing the program’s advancement with the FDA.
The webcast can be accessed here, and slides are available on Revelation’s website. Revelation intends to publish these results and ongoing data analysis.
Mike Porter, Investor Relations, Porter LaVay & Rose Inc., Email: mike@plrinvest.com
Chester Zygmont, III, Chief Financial Officer, Revelation Biosciences Inc., Email: czygmont@revbiosciences.com
Source: Revelation Biosciences
